Orthopedic Surgical Instrument Classification Rules
Summary
The Food and Drug Administration (FDA, the Agency, or we) is classifying orthopedic manual surgical instrumentation for use with total disc replacement devices into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of orthopedic manual surgical instrumentation for use with total disc replacement devices. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Compliance Requirements
- #1
Technical specifications regarding geometry of the instruments must be specified and validated to demonstrate that the instruments can safely position, place, or remove the implant.; The patient contacting components of the device must be demonstrated to be biocompatible.; Performance data must demonstrate that reprocessing of reusable devices that are provided non-sterile, or sterilization of devices provided sterile, is validated.; Labeling must include identification of implant(s) and instruments which have been validated for use together.; Labeling must include validated methods and instructions for reprocessing any reusable parts.; This device is subject to premarket notification requirements under section 510(k) of the FD&C Act (21 U.S.C. § 360(k)).; For a device to fall within this classification, and thus avoid automatic classification in class III, it would have to comply with the special controls named in this final order.
Market Impacts
Reclassification from potential class III to class II with special controls reduces regulatory burden and enhances market access for manufacturers of orthopedic manual surgical instrumentation for total disc replacement devices; Premarket notification requirements under section 510(k) of FD&C Act apply to all devices in this classification, requiring 510(k) clearance before marketing; Establishment of clear regulatory pathway under section 513(f)(6) of FD&C Act allows manufacturers to request accessory classification distinct from parent devices; Mandatory compliance with special controls including technical specifications validation, biocompatibility testing, reprocessing/sterilization validation, and specific labeling requirements
Validated Company Impacts
MERIT MEDICAL SYSTEMS INC
Merit Medical Systems primarily manufactures and distributes interventional, diagnostic, and therapeutic devices focused on cardiology, radiology, and endoscopy procedures, not orthopedic surgical instrumentation for total disc replacement. Their business operations center on vascular access, embolization, and drainage products rather than spinal surgery devices or orthopedic manual surgical instruments. The rule directly addresses two of the company's top regulatory risks - FDA regulatory clearance requirements and sterilization service provider dependency. The 510(k) premarket notification requirements and sterilization validation mandates align precisely with the company's identified regulatory compliance challenges.
STRYKER CORP
Stryker's Orthopaedics segment directly manufactures orthopedic implants and surgical instruments for joint replacement procedures, which aligns precisely with the rule's focus on orthopedic manual surgical instrumentation for total disc replacement devices. The company's medical device manufacturing operations would be subject to the FDA's technical specifications validation, biocompatibility testing, and labeling requirements for these surgical instruments. The rule focuses on specific medical device manufacturing compliance requirements for orthopedic surgical instrumentation, while the company's disclosed risks are primarily financial, operational, and market-related with only one generic regulatory compliance risk mentioned. There is minimal overlap as the company's regulatory risk appears to be general legal/liability concerns rather than specific medical device manufacturing compliance requirements.
ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet is a global medical technology leader specializing in orthopedic reconstructive products, directly manufacturing and marketing the exact type of orthopedic manual surgical instrumentation targeted by this FDA rule. The company's core business operations involve designing, manufacturing, and distributing orthopedic devices including spinal surgery instrumentation, placing them squarely within the scope of this classification and its compliance requirements. The federal rule focuses entirely on medical device manufacturing compliance requirements including technical specifications validation, biocompatibility testing, and sterilization processes, while the company's only disclosed risk factor relates to cybersecurity threats in technology operations. There is no overlap between the regulatory compliance risks addressed by this medical device rule and the company's cybersecurity risk profile.